• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study.COVID-19 患者恢复期延长的预测因素:一项横断面研究。
Eur J Med Res. 2021 May 6;26(1):41. doi: 10.1186/s40001-021-00513-x.
2
Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study.埃塞俄比亚西部沃莱加大学转诊医院(WURH)治疗中心收治的新冠肺炎患者的康复时间及其预测因素:回顾性队列研究的生存分析
PLoS One. 2021 Jun 10;16(6):e0252389. doi: 10.1371/journal.pone.0252389. eCollection 2021.
3
Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection?Covid-19 门诊患者-发热对 SARS-CoV-2 感染是否有帮助?
PLoS One. 2021 Feb 3;16(2):e0246312. doi: 10.1371/journal.pone.0246312. eCollection 2021.
4
A Large Retrospective Study of Epidemiological Characteristics of COVID-19 Patients in the North of Iran: Association between SARS-CoV-2 RT-PCR Ct Values with Demographic Data.伊朗北部 COVID-19 患者的大回顾性研究:SARS-CoV-2 RT-PCR Ct 值与人口统计学数据的关联。
Int J Clin Pract. 2022 Feb 28;2022:1455708. doi: 10.1155/2022/1455708. eCollection 2022.
5
COVID-19 viral load not associated with disease severity: findings from a retrospective cohort study.COVID-19 病毒载量与疾病严重程度无关:一项回顾性队列研究的结果。
BMC Infect Dis. 2021 Jul 16;21(1):688. doi: 10.1186/s12879-021-06376-1.
6
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
7
Predictors of COVID-19 related death in diabetes patients: A case-control study in Iran.伊朗一项病例对照研究:预测糖尿病患者 COVID-19 相关死亡的因素。
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102149. doi: 10.1016/j.dsx.2021.05.022. Epub 2021 May 21.
8
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.加拿大疫情第一阶段住院和重症监护的 COVID-19 患者的特征和结局:一项全国性队列研究。
CMAJ Open. 2021 Mar 8;9(1):E181-E188. doi: 10.9778/cmajo.20200250. Print 2021 Jan-Mar.
9
Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection.住院的轻症/普通型 COVID-19 患者中,SARS-CoV-2 核酸检测转阴时间延长患者的临床特征。
BMC Infect Dis. 2021 Feb 3;21(1):141. doi: 10.1186/s12879-021-05851-z.
10
Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study.沙特阿拉伯非重症监护病房 COVID-19 患者的临床特征:一项描述性横断面研究。
J Infect Public Health. 2020 Nov;13(11):1639-1644. doi: 10.1016/j.jiph.2020.09.003. Epub 2020 Sep 21.

引用本文的文献

1
Association Between Severity of COVID-19 Infection and Persistent Dyspnea in Recovered Adults: A Cross-Sectional Study.新冠病毒感染康复成年患者的严重程度与持续性呼吸困难之间的关联:一项横断面研究
Cureus. 2025 Jun 9;17(6):e85666. doi: 10.7759/cureus.85666. eCollection 2025 Jun.
2
Evaluating the Impact of Age and Comorbidities on COVID-19 Outcomes and Healthcare Costs: A Comparative Analysis of Immunocompromised and General Populations in the United States (EON-US).评估年龄和合并症对新冠病毒疾病结局及医疗成本的影响:美国免疫功能低下人群与普通人群的比较分析(EON-US)
Infect Dis Ther. 2025 Jun;14(6):1343-1367. doi: 10.1007/s40121-025-01160-z. Epub 2025 Jun 4.
3
Incidence of recovery rate and predictors among hospitalized COVID- 19 infected patients in Ethiopia; a systemic review and meta-analysis.埃塞俄比亚住院的新冠病毒感染患者的康复率及预测因素发生率;一项系统评价与荟萃分析
BMC Public Health. 2025 May 3;25(1):1644. doi: 10.1186/s12889-025-22841-x.
4
Time to recovery of COVID-19 patients and its predictors: a retrospective cohort study in HUCSH, Sidama, Ethiopia.新冠病毒疾病患者的康复时间及其预测因素:埃塞俄比亚锡达马胡胡谢医院的一项回顾性队列研究
BMC Public Health. 2025 Jan 7;25(1):74. doi: 10.1186/s12889-024-21229-7.
5
A combined neural ODE-Bayesian optimization approach to resolve dynamics and estimate parameters for a modified SIR model with immune memory.一种结合神经常微分方程-贝叶斯优化的方法,用于解析具有免疫记忆的改进SIR模型的动力学并估计参数。
Heliyon. 2024 Sep 24;10(19):e38276. doi: 10.1016/j.heliyon.2024.e38276. eCollection 2024 Oct 15.
6
COVID-19 Recovery Time and Its Predictors among Hospitalized Patients in Designated Hospitals in the Madhesh Province of Nepal: A Multicentric Study.尼泊尔马德西省指定医院住院患者的新冠病毒病康复时间及其预测因素:一项多中心研究
Healthcare (Basel). 2024 Aug 24;12(17):1691. doi: 10.3390/healthcare12171691.
7
Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination.卡斯特曼病患者报告新冠病毒疾病症状较轻,且对新冠病毒疫苗接种产生体液免疫反应。
Blood Neoplasia. 2024 Mar;1(1). doi: 10.1016/j.bneo.2024.100002. Epub 2024 Feb 15.
8
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study.评估美国商业保险免疫功能低下人群中不同变异株 COVID-19 的负担和成本:正在进行的 EPOCH-US 研究的最新结果和趋势。
Adv Ther. 2024 Mar;41(3):1075-1102. doi: 10.1007/s12325-023-02754-0. Epub 2024 Jan 13.
9
Time to recovery and its determinant factors among patients with COVID-19 in Assosa COVID-19 treatment center, Western Ethiopia.埃塞俄比亚西部阿索萨新冠治疗中心新冠肺炎患者的康复时间及其决定因素。
Pneumonia (Nathan). 2023 Nov 5;15(1):17. doi: 10.1186/s41479-023-00119-3.
10
Genetic clues to COVID-19 severity: exploring the stromal cell-derived factor-1/CXCL12 rs2839693 polymorphism in adult Egyptians.遗传线索与 COVID-19 严重程度:探索成年埃及人基质细胞衍生因子-1/CXCL12 rs2839693 多态性。
BMC Infect Dis. 2023 Oct 19;23(1):702. doi: 10.1186/s12879-023-08691-1.

本文引用的文献

1
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?早期联合使用现有 HIV 抗病毒药物:治疗 COVID-19 的有效方法?
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2435-2448. doi: 10.26355/eurrev_202103_25285.
2
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
3
Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience.血管紧张素 II 受体阻滞剂会增加感染 SARS-CoV-2 的风险吗?一项真实世界的经验。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):523-526. doi: 10.26355/eurrev_202101_24424.
4
Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology.动脉高血压作为与COVID-19病理相关的风险合并症。
Int J Hypertens. 2020 Dec 4;2020:8019360. doi: 10.1155/2020/8019360. eCollection 2020.
5
Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.全球 COVID-19 荟萃分析显示,男性性别是死亡和 ICU 入院的风险因素。
Nat Commun. 2020 Dec 9;11(1):6317. doi: 10.1038/s41467-020-19741-6.
6
Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.伊拉克 COVID-19 肺炎合并糖尿病患者住院不良结局和恢复的预测因素。
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):33-38. doi: 10.1016/j.dsx.2020.12.014. Epub 2020 Dec 5.
7
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
8
Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age.加拿大 COVID-19 的发病率、临床特征和结局:性别和年龄的影响。
J Ovarian Res. 2020 Nov 24;13(1):137. doi: 10.1186/s13048-020-00734-4.
9
Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection.2019冠状病毒病(COVID-19)感染住院患者的冠状动脉疾病
Open Heart. 2020 Nov;7(2). doi: 10.1136/openhrt-2020-001428.
10
COVID-19 and diabetes mellitus: from pathophysiology to clinical management.新型冠状病毒肺炎与糖尿病:从病理生理学到临床管理。
Nat Rev Endocrinol. 2021 Jan;17(1):11-30. doi: 10.1038/s41574-020-00435-4. Epub 2020 Nov 13.

COVID-19 患者恢复期延长的预测因素:一项横断面研究。

Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study.

机构信息

Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.

Department of Infectious Disease, Imam Khomeini Hospital, Tehran University of Medical Sciences, Blv. Keshavarz, Tehran, 1419733141, Iran.

出版信息

Eur J Med Res. 2021 May 6;26(1):41. doi: 10.1186/s40001-021-00513-x.

DOI:10.1186/s40001-021-00513-x
PMID:33957992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8100933/
Abstract

BACKGROUND

The clinical course of COVID-19 may vary significantly. The presence of comorbidities prolongs the recovery time. The recovery in patients with mild-to-moderate symptoms might take 10 days, while in those with a critical illness or immunocompromised status could take 15 days. Considering the lack of data about predictors that could affect the recovery time, we conducted this study to identify them.

METHODS

This cross-sectional study was implemented in the COVID-19 clinic of a teaching and referral university hospital in Tehran. Patients with the highly suggestive symptoms who had computed tomography (CT) imaging results with typical findings of COVID-19 or positive results of reverse transcriptase-polymerase chain reaction (RT-PCR) were enrolled in the study. Inpatient and outpatient COVID-19 participants were followed up by regular visits or phone calls, and the recovery period was recorded.

RESULTS

A total of 478 patients were enrolled. The mean age of patients was 54.11 ± 5.65 years, and 44.2% were female. The median time to recovery was 13.5 days (IQR: 9). Although in the bivariate analysis, multiple factors, including hypertension, fever, diabetes mellitus, gender, and admission location, significantly contributed to prolonging the recovery period, in multivariate analysis, only dyspnea had a significant association with this variable (p = 0.02, the adjusted OR of 2.05; 95% CI 1.12-3.75).

CONCLUSION

This study supports that dyspnea is a predictor of recovery time. It seems like optimal management of the comorbidities plays the most crucial role in recovery from COVID-19.

摘要

背景

COVID-19 的临床病程可能有很大差异。合并症的存在会延长恢复时间。轻症至中度症状患者的恢复可能需要 10 天,而重症或免疫功能低下患者的恢复可能需要 15 天。考虑到缺乏可能影响恢复时间的预测因素的数据,我们进行了这项研究以确定这些因素。

方法

这是一项在德黑兰一所教学和转诊大学医院的 COVID-19 诊所进行的横断面研究。具有高度提示性症状且 CT 影像学结果具有 COVID-19 典型表现或逆转录酶-聚合酶链反应(RT-PCR)阳性结果的患者被纳入研究。住院和门诊 COVID-19 患者通过定期就诊或电话随访进行随访,并记录恢复时间。

结果

共纳入 478 例患者。患者的平均年龄为 54.11±5.65 岁,44.2%为女性。中位恢复时间为 13.5 天(IQR:9)。虽然在单变量分析中,包括高血压、发热、糖尿病、性别和入院地点在内的多种因素显著延长了恢复时间,但在多变量分析中,只有呼吸困难与该变量有显著相关性(p=0.02,调整后的 OR 为 2.05;95%CI 1.12-3.75)。

结论

本研究支持呼吸困难是恢复时间的预测因素。似乎合并症的最佳管理在 COVID-19 的恢复中起着最重要的作用。